Share
1,431 Posts.
lightbulb Created with Sketch. 135
clock Created with Sketch. 03/09/24
19:59
Share
Originally posted by jetrodder:
↑
The whole Generic's Strategy that started back in 2015, was based initially on Efinaconazole. At the time a US$200M plus seller. We were told that ACR won the Patent court case in 2017. But seeing it's now 7 years since that win, and not a single Pharma Company has been allowed to launch a Generic, it feels more like a loss. Anywhere from $2-4 million was spent developing this ANDA, and to date has earned nothing. And an equal amount was spent developing a Axion Generic, was launched briefly then was pulled. That's anywhere form $4 to $7M spent on 2 ANDA's with sweet FA to show for it. Jet
Expand
nah. ACR didn’t win the case. ACR reached an agreement with the patent holder. ACR will be allowed to launch the product after the agreed date.
